Oxytocin vs PT-141 (bremelanotide) for low sexual desire
Every row cites its source. Where a cell reflects our own reading of the evidence rather than an external source, the row says so.
These two are marketed to the same audience and are frequently discussed together, so here is what separates them on the record. This is a factual comparison, not a recommendation of either.
| Aspect | Intranasal oxytocin | Bremelanotide (PT-141) | Source |
|---|---|---|---|
| Molecule and mechanism | Cyclic nonapeptide hormone, oxytocin-receptor agonist | Synthetic melanocortin receptor agonist, a different peptide family with a different target | source |
| FDA status | No approved nasal product; approved only as an injectable obstetric drug | Approved as Vyleesi, NDA 210557, subcutaneous autoinjector | source |
| Approved indication | None for sexual function | Acquired, generalized hypoactive sexual desire disorder in premenopausal women, with labeled limitations of use excluding postmenopausal women and men, and excluding performance enhancement | source |
| Route and timing | Nasal spray; the sexual-function trial used 32 IU within 50 minutes before intercourse | 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity, no more than one dose in 24 hours and no more than 8 doses per month | source |
| Best controlled result for sexual function | 22-week randomized crossover in 30 women: Female Sexual Function Index rose 26% on oxytocin and 31% on placebo, no significant treatment effect | Approved on its own registrational program, which this site does not restate secondhand; see the sister site for the trial detail | source |
| What it did not change | Sexual drive, arousal, erection and lubrication were unchanged at 24 IU in a couples study; secondary post-orgasm measures shifted | Labeled as not indicated to enhance sexual performance | source |
| Key contraindication on the label | No nasal label exists; the injectable label lists obstetric contraindications and hypersensitivity | Contraindicated in uncontrolled hypertension or known cardiovascular disease | source |